Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

  • This share is currently suspended. It was suspended at a price of 1.2699
  • There is currently no data for ONC

Grant of options

8 Nov 2016 18:25

RNS Number : 6778O
Oncimmune Holdings PLC
08 November 2016
 

8 November 2016

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 8 November 2016, options over ordinary shares of the Company were awarded to certain Directors and certain PDMRs under the Company's 2016 Share Option Plan (an amalgamation of the Company's 2005 and 2007 Share Option Plans) as follows.

 

Name

Position

Number of share options awarded

Option exercise price per share (pence)

Percentage of issued share capital (%)

Meinhard Schmidt

Non-executive Chairman

120,370

108

0.236

Geoffrey Hamilton-Fairley

Chief Executive Officer

528,273

1

1.035

119,875

108

0.235

Andrew Millet

Chief Financial Officer

92,593

108

0.181

Andrea Murray

Chief Operational Scientist

41,667

108

0.082

Maarten Brusse

Chief Commercial Officer

74,074

108

0.145

 

The options are subject to the rules of the 2016 Share Option Plan and vest in five equal annual parts, the first fifth vesting on 7 November 2017 and each year thereafter for a further four years, subject to continued employment. Unless otherwise indicated in the table above, the options are exercisable at 108 pence, being the mid-market closing price of the Company's ordinary shares on 7 November 2016

 

For further information:

 

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

 

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

+44 (0) 203 829 5000

 

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Meinhard Schmidt

2

Reason for the notification

a)

Position/status

 

Non-Executive Chairman, Director

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

120,370

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

120,370

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Geoffrey Hamilton-Fairley

2

Reason for the notification

a)

Position/status

 

Chief Executive Officer

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

528,273

N/A

119.875

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

648,148

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Andrew Millet

2

Reason for the notification

a)

Position/status

 

Chief Financial Officer

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

92,593

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

92,593

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Andrea Murray

2

Reason for the notification

a)

Position/status

 

Chief Operational Scientist and PDMR

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

41,667

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

41,667

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

 

Maarten Brusse

2

Reason for the notification

a)

Position/status

 

Chief Commercial Officer and PDMR

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over ordinary shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

N/A

74,074

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

74,074

e)

Date of the transaction

 

8 November 2016

f)

Place of the transaction

 

 

N/A

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBIBDBSDGBGLI
Date   Source Headline
28th Apr 20257:00 amRNSCancellation - ONCIMMUNE HOLDINGS PLC
26th Mar 202512:45 pmRNSAppointment of Administrators & Nomad Resignation
19th Mar 20257:00 amRNSHolding(s) in Company
17th Mar 20257:30 amRNSSuspension - Oncimmune Holdings Plc
17th Mar 20257:00 amRNSIntention to Appoint Administrators and Suspension
14th Mar 20257:00 amRNSBlock Listing Return
10th Mar 20251:39 pmRNSResult of GM
27th Feb 20254:18 pmRNSResult of AGM
24th Feb 20257:00 amRNSStrategic update
18th Feb 20257:00 amRNSHolding(s) in Company
12th Feb 20257:01 amRNSBlock Listing Return
12th Feb 20257:00 amRNSPosting of Notice of General Meeting
10th Feb 20257:00 amRNSFinal Results
4th Feb 202510:38 amRNSHolding(s) in Company
3rd Feb 20257:00 amRNSNotice of Annual General Meeting
31st Jan 20257:00 amRNSTrading Update
10th Dec 20243:36 pmRNSHolding(s) in Company
4th Dec 20241:38 pmRNSHolding(s) in Company
13th Nov 20245:06 pmRNSHolding(s) in Company
13th Nov 202411:41 amRNSHolding(s) in Company
12th Nov 20245:17 pmRNSHolding(s) in Company
12th Nov 20244:49 pmRNSHolding(s) in Company
11th Nov 202411:15 amRNSDirector/PDMR Shareholding
8th Nov 20242:37 pmRNSResults of General Meeting and Total Voting Rights
31st Oct 20245:07 pmRNSResult of Retail Offer
31st Oct 20247:00 amRNSTrading Update
23rd Oct 20244:12 pmRNSPosting of Circular and Notice of General Meeting
18th Oct 20243:05 pmRNSResult of Placing & Issue of Equity
18th Oct 20248:00 amRNSRetail Offer
18th Oct 20247:47 amRNSFundraising and Amendments to Facility
9th Sep 20247:00 amRNSTrading Update
2nd Sep 20247:00 amRNSContract Win
9th Aug 20247:00 amRNSUS$1.5m Contract Win with Top 10 Pharma Company
24th Jun 202411:18 amRNSHolding(s) in Company
17th Jun 20242:30 pmRNSHolding(s) in Company
29th May 20245:45 pmRNSHolding(s) in Company
21st May 20247:00 amRNSInterim Results
17th May 202410:11 amRNSInvestor Presentation via Investor Meet Company
9th May 20243:08 pmRNSHolding(s) in Company
26th Apr 20247:00 amRNSAppointment of Nominated Adviser and Joint Broker
25th Apr 202410:44 amRNSHolding(s) in Company
2nd Apr 202411:34 amRNSResult of General Meeting
2nd Apr 20248:00 amRNSTotal Voting Rights
26th Mar 202411:18 amRNSHolding(s) in Company
13th Mar 20245:32 pmRNSBlock Listing Return
6th Mar 20243:02 pmRNSPosting of Notice of General Meeting
1st Mar 20241:00 pmRNSInvestor Presentation via Investor Meet Company
29th Feb 202411:19 amRNSHolding(s) in Company
29th Feb 20247:00 amRNSFinal Results
26th Feb 202411:30 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.